To study the pattern of seroconversion for SARS-CoV-2 IgG antibodies in COVID-infected cancer patients and to correlate it clinically - A cross-sectional study.

Abstract

Though as per literature cancer is also consider an associated risk factor for morbidity and mortality for covid infection but practically most of the cancer patients showed no symptoms with less mortality in second wave of pandemic. So this cross sectional comparative analysis study was designed to see the prevalence of sero-conversion for SARS -coV for IgG in covid infected cancer patients and to compare the IgG antibodies level between covid infected cancer patients and covid infected healthy persons. Covid-19 antibody screening of covid recovered cancer patients as well as covid recovered healthy persons was done in department of Transfusion Medicine.IgG antibody for COVID-19 was detected using microtiter plate with whole-cell antigen coating, an in-house validated kit by NIV ICMR3. Prevalence of sero-conversion was noted down in both the groups and compared. There was more infectivity rate in second covid wave. Case fatality rate was much lesser as compared to 1st wave in cancer patients. In cancer patients maximum seroconversion was seen in younger group i.e. 21-30 yrs. of age, this was in contrast to finding in general population, where minimum seroconversion was seen in younger age group. It was observed that more prevalence of sero conversion was seen in general population as compared to cancer patients, but difference was non-significant. Though cancer patients showed less rate of seroconversion as compared to normal healthy person, but none of them showed any moderate or severe symptoms inspite of being a risk factor for severity of covid. Though larger study are required to comment on statistical conclusion.